PMID- 9884508
OWN - NLM
STAT- MEDLINE
DCOM- 19990413
LR  - 20190822
IS  - 0387-5911 (Print)
IS  - 0387-5911 (Linking)
VI  - 72
IP  - 11
DP  - 1998 Nov
TI  - [Clinical study of itraconazole for systemic fungal infections complicated with 
      hematological malignancies--multicenter cooperative study. West-Japan Systemic 
      Fungal Infection Study Group].
PG  - 1208-18
AB  - Itraconazole, an oral antifungal agent, was evaluated for the clinical efficacy 
      and safety in patients documented or suspected of systemic fungal infection (SFI) 
      complicated with hematological malignancies. The data was also evaluated 
      according to serological tests and fungal culture. Out of a total of 79 patients, 
      the clinical efficacy of itraconazole was evaluated in 52 patients, comprising 4 
      patients with proven SFI, 33 with clinical SFI, and 15 with suspected SFI. The 
      overall efficacy was 67.3% (35/52), in which 25.0% in the established SFI group 
      (1/4), 78.8% in the clinical SFI group (26.33), and 53.3% in the suspected SFI 
      (8/15). When assessed according to the severity of SFI, the effectiveness rates 
      were 75.0% in the mild group (15/20), 76.2% in the moderate group (16/21), and 
      36.4% in the severe group (4/11), resulting in significantly higher rates in the 
      mild and the moderate groups than in the severe group (p = 0.0479). Out of the 10 
      patients who were switched from the previous antifungals, 7 patients were judged 
      as showing marked or good responses. All of these patients were switched from 
      intravenous fluconazole therapy. With respect to the safety of itraconazole, 
      among 79 patients eligible for safety evaluation, adverse events such as hepatic 
      dysfunction, increase in GOT and/or GPT, nausea and vomiting, and chest pain were 
      observed in 6 patients (7.6%), and itraconazole may have been associated with 
      them. As a conclusion, itraconazole proved to be effective and safe on SFI 
      developed in patients with various hematological malignancies.
FAU - Shiku, H
AU  - Shiku H
AD  - Osaka Medical Center for Cancer and Cardiovascular Diseases.
FAU - Horiuchi, A
AU  - Horiuchi A
FAU - Kuramoto, A
AU  - Kuramoto A
FAU - Harada, M
AU  - Harada M
FAU - Niho, Y
AU  - Niho Y
LA  - jpn
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
PL  - Japan
TA  - Kansenshogaku Zasshi
JT  - Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious 
      Diseases
JID - 0236671
RN  - 0 (Antifungal Agents)
RN  - 304NUG5GF4 (Itraconazole)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antifungal Agents/*administration & dosage
MH  - Drug Administration Schedule
MH  - Female
MH  - Hematologic Neoplasms/*complications
MH  - Humans
MH  - Immunocompromised Host
MH  - Itraconazole/*administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Mycoses/complications/*drug therapy
MH  - Opportunistic Infections/*complications
EDAT- 1999/01/13 00:00
MHDA- 1999/01/13 00:01
CRDT- 1999/01/13 00:00
PHST- 1999/01/13 00:00 [pubmed]
PHST- 1999/01/13 00:01 [medline]
PHST- 1999/01/13 00:00 [entrez]
AID - 10.11150/kansenshogakuzasshi1970.72.1208 [doi]
PST - ppublish
SO  - Kansenshogaku Zasshi. 1998 Nov;72(11):1208-18. doi: 
      10.11150/kansenshogakuzasshi1970.72.1208.